| [1] |
WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong.
Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
|
| [2] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
| [3] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
| [4] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
| [5] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
| [6] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|
| [7] |
LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong.
Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
|
| [8] |
DENG Kunhong, LIU Yaxin, SUN Yuanyuan, CHEN Wenjing, YANG Nan, HU Zhanqing, CHEN Kaifeng, HUANG Jie, XIANG Yuxia, YANG Guoping.
Literature analysis of the design and results of the First-In-Human clinical trials of drugs from 2009 to 2020
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 77-85.
|
| [9] |
ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang.
Research progress of PARP inhibitors in pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
|
| [10] |
SHE Zhihua, CHEN Zhou, LIANG Songyue.
Construction of informatization system of drug clinical trials ethical review based on cloud architecture
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
|
| [11] |
SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan.
Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
|
| [12] |
OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin.
Ethical issues and countermeasures of early phase trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
|
| [13] |
HUANG Lihong, WANG Ling, YAN Fangrong, WEI Zhaohui, ZHAO Yang, XIA Jielai, CHEN Feng.
New perspectives on the principle of intention to treat in clinical trials#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 449-453.
|
| [14] |
Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning.
Research progress in clinical trials of targeted drugs for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
|
| [15] |
ZHANG Qian, HU Wei, YU Bin, QIN Huiling, CHEN Mingzhuang, LU Chao.
Information construction of drug clinical trials based on literature analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 182-189.
|
